Clinical Report: Stockholm3 Prostate Cancer Test Outperforms PSA Screening

Overview

The Stockholm3 test detected over twice as many clinically significant prostate cancers compared to age-based PSA screening in a study involving 12,670 men. This multivariable blood test demonstrated a higher detection rate while maintaining similar false-positive rates.

Background

Prostate cancer screening is critical for early detection and treatment, particularly for clinically significant cases. Traditional PSA screening has limitations, including lower sensitivity and specificity.

Data Highlights

Key Findings

• Stockholm3 identified 90% of clinically significant prostate cancers compared to 74% for PSA ≥3 ng/ml.
• The false-positive rate for Stockholm3 was comparable to PSA ≥3 ng/ml, but higher than PSA ≥4 ng/ml.
• Decision-curve analyses indicated a higher overall clinical benefit for Stockholm3 across various biopsy decision thresholds.
• Stockholm3 referred more men for additional diagnostic assessments than conventional PSA screening.
• The study involved a population-based analysis of men aged 50 to 74 years in Sweden.

Clinical Implications

Clinicians should consider the increased referral rates for diagnostic assessments associated with this test.

Conclusion

The Stockholm3 test shows potential in enhancing prostate cancer detection compared to traditional PSA screening.

Related Resources & Content

1. Conexiant, Annals of Internal Medicine, 2026 -- Stockholm3 Detected More Significant Prostate Cancers Than PSA
2. The Pathologist, 2026 -- Stockholm3 Test Cuts MRIs in Prostate Screening
3. The ASCO Post, 2026 -- Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
4. The ASCO Post — Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
5. EAU Guidelines on Prostate Cancer 2026
6. AUA/SUO Guideline on Prostate Cancer Screening
7. Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline
8. Should I Get Screened for Prostate Cancer? | Prostate Cancer | CDC
9. Stockholm3-MRI population-based screening: Two-year outcomes comparing Stockholm3 and PSA. | Journal of Clinical Oncology
10. New blood test detects more high-risk prostate cancer cases | Karolinska Institutet
11. Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial - PubMed